MRI-based personalisation of neoadjuvant chemotherapy duration in HER2-positive early breast cancer (TRAIN-3): primary results from a multicentre, single-arm, phase 2 study

Articles MRI-based personalisation of neoadjuvant chemotherapy duration in HER2-positive early breast cancer (TRAIN-3): primary results from a multicentre, single-arm, phase 2 study +... Fleur M LouisAnna van der VoortMette S van RamshorstAntonios DaletzakisIngrid A MandjesInge Kemperand others The Lancet OncologyVol. 27No. 3p349–360 https://www.thelancet.com/collections/tumour-imaging?dgcid=hubspot_email_infocusalerts-oncology_feature&parent=001611&startPage=&utm_campaign=infocusalerts-oncology&utm_medium=email&_hsenc=p2ANqtz-8zORBPB5oOMjMGjJRFxmbfxCo4WHwqNEwUXxyQ-eYVpxP02ggQAvFUEw3VnO-p4q2Pdadgfwsl8UVZYhcs9ozBF5z-1w&_hsmi=408798171&utm_content=408446946&utm_source=hs_email Published: February 16, 2026